CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 83 enrolled
Drug / intervention
rabeprazole-based triple therapy plus bismuth H. pylori eradication therapydrug
Likely dose
rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07408271
NCT07408271N/ACompleted
CompareCT.gov

The Impact of Rabeprazole-based Triple Therapy Plus Bismuth for First-line Helicobacter Pylori Eradication on the Vaginal Microecology Change: a Prospective, Randomized Controlled Trial

Second Affiliated Hospital, School of Medicine, Zhejiang University·observational·Posted Feb 13, 2026·Updated Feb 13, 2026

In Brief

An observational study evaluating rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy for Helicobacter Pylori Infection and Helicobacter Pylori Eradication Antibiotic. Completed, enrolled 83 participants across 1 site.

Detailed Summary

This clinical controlled study enrolled 73 H. pylori（Helicobacter Pylori ）-infected female participants, stratified into reproductive-age and menopausal cohorts, alongside 10 non-infected controls. Through integrated analysis of routine vaginal discharge parameters and longitudinal amplicon sequencing data of vaginal discharge, investigators analyzed the impact of H. pylori eradication therapy on vaginal microecology.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHelicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 13, 2026
Enrollment StartMar 24, 2023
Primary CompletionMar 24, 2023
Study CompletionMar 24, 2024
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 5 months ago

Interventions

rabeprazole-based triple therapy plus bismuth H. pylori eradication therapydrug

rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy: Rabeprazole 10 mg twice a day (Eisai Pharmaceutical Co., Ltd.), Colloidal Bismuth Pectin 220 mg twice a day (Shanxi Ante Biological Pharmaceutical Co., Ltd.), Amoxicillin 1.0 g twice a day (CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.), and Clarithromycin 0.5 g twice a day (Shanghai Abbott Pharmaceutical Co., Ltd.)